You are here: Industry Insights > SVP

News List

Oncternal Therapeutics Appoints Pablo Urbaneja as SVP, Corporate Development firstwordpharma
July 02, 2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.
CSafe Global Appoints SVP of Technology and Innovation contractpharma
April 23, 2021
CSafe Global, a leader in temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals, has appointed Venu Vinjamaram to the company’s senior leadership team as senior vice president of technology and innovation.
PCI Pharma Services Appoints SVP, CFO contractpharma
March 03, 2021
Tom De Weerdt brings more than 20 years of experience in financial leadership roles at large, global corporations.
Lilly Apoints SVP, CFO contractpharma
February 10, 2021
Anat Ashkenazi replaces Josh Smiley, who has resigned and will be leaving the company.
Inozyme Pharma Appoints SVP, Regulatory Affairs contractpharma
November 10, 2020
Inozyme Pharma Inc. has appointed Kevin B. Johnson, Ph.D., MBA, as senior vice president, regulatory affairs, effective immediately.
Avomeen Names SVP of Lab Operations contractpharma
October 30, 2020
Avomeen has appointed Luke Miller, Ph.D. as its senior vice president of lab operations. In this position, Miller will further strengthen and expand Avomeen’s laboratory operations to support the company’s continued growth.
Abenza Appoints SVP and Site Head contractpharma
October 10, 2020
Giovanni Escobar brings over 27 years’ experience in the Pharmaceutical industry.
Aprecia Appoints Regulatory Affairs SVP contractpharma
September 18, 2020
Kathi Rinesmith to oversee strategic regulatory affairs for the company's expanding pipeline of 3D-printed pharmaceuticals.
Lyra Appoints SVP of Research and Development contractpharma
July 08, 2020
Dr. Robert Richard joins from Anika Therapeutics.
Provention Bio Appoints Clinical Development SVP contractpharma
August 21, 2019
Dr. Kell will lead the PRV-031 program, including the oversight of the Phase III PROTECT study and support of regulatory submissions.

Previous page 1 2 Next page